November 2, 2020 (Shanghai, China) - GenFleet Therapeutics, a clinical-stage biotechnology company focusing cutting-edge therapies in oncology and immunology, today announced the appointment of Dr. Yu Wang as Chief Medical Officer and Dr. Haige Shen as Senior Vice President of clinical development for the company. In their roles, Dr. Yu Wang will be responsible for the strategic planning and operation of GenFleet's clinical development, and Dr. Haige Shen will serve as the clinical department executive and lead the clinical data science group.
Yu Wang, M.D./Ph.D., brings over 15 years of experiences in clinical development and his expertise focuses on anti-tumor therapeutics for solid tumors and hematological malignancies. He completed postdoctoral training at Barbara Karmanos Cancer Institute in US and his career in the industry came with multiple multinational pharmaceutical companies (Eli Lilly, GSK, Sanofi APTSU and Novartis) where he worked as a medical director in the full clinical development of oncology products. Prior to GenFleet, he was the co-founder of ZenRhyme Advisory and served as a part-time Chief Medical Officer for many biotech and pharmaceutical companies.
Haige Shen, Ph.D., has her drug development experiences ranging from data analysis in drug discovery to early-phase & full clinical development in both global and China’s local settings. Holding Ph.D. degrees in bioinformatics and electronic engineering, she led the statistical work in multiple global programs while working with Novartis and her career was enriched with early-phase clinical development of first-in-class anti-cancer therapies in Translational Clinical Oncology. Before joining GenFleet, she was also the co-founder of ZenRhyme Advisory, offering consultation on clients' clinical development strategies.
“We are excited to welcome Dr. Wang and Dr. Shen as executives of clinical development, which is symbolic of GenFleet's growth into a clinical-stage biotechnology company. We are confident in their leadership to strengthen the R&D platform and the clinical research progress of our first-in-class pipeline." said Dr. Qiang Lu, Co-founder and Chairman of Board of GenFleet.
"Dr. Wang and Dr. Shen had already worked as part-time consultants with GenFleet’s clinical team to boost the progress of our first-in-class pipeline. We look forward to their full-time engagement, as GenFleet's clinical development proceeds with more strategic steps forward." Said Dr. Jiong Lan, Co-founder and Chief Executive Officer of GenFleet.
“I am delighted to be joining such a dynamic and forward-thinking biotech as Genfleet. Making efforts will staff members, we will be well-positioned to build up Genfleet into a world-class biotechnology company,” said Dr. Yu Wang.
“We've always appreciated the inclusiveness of GenFleet’s corporate culture through years of cooperation. In future we will work together to improve our R&D productivity and deliver more beneficial therapies to serve the enormous unmet medical needs,” said Dr. Haige Shen.
